Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | PDXK | O00764 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.54 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxine SCHEMBL3761205 | 0.89 | KDM4E (0.92) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.88 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30267871 | 0.88 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL13498731 | 0.88 | KDM4E (0.60) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.88 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL2322958 | 0.88 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL28805884 | 0.87 | KDM4E (0.89) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL28837806 | 0.87 | KDM4E (0.89) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL26097027 | 0.87 | KDM4E (0.89) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11074402 | 0.87 | KDM4E (0.76) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017090007-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND HEPATIC DISEASES | RAO M SURYA (IN) | 2017-06-01 | — | — | WO | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| WO-2014122621-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC CONDITIONS AND NEUROMUSCULAR DISEASES | KANDULA MAHESH (IN) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014115098-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION | KANDULA MAHESH (IN) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014091465-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND LIPID DISORDERS | KANDULA MAHESH (IN) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014091467-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATION | KANDULA MAHESH (IN) | 2014-06-19 | — | — | WO | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-4144342-A | ANTIARTHRITIC AND ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | KDM4E 3628/4885ALDH1A1 1969/4885HPGD 2169/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | KDM4E 958/4885ALDH1A1 4455/4885HPGD 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.